Hoffmann, Donata

SARS-CoV-2 spike D614G change enhances replication and transmission

Zhou, B., Thao, T. T. N., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A., King, J., Steiner, S., Kelly, J. N., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 538

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 48

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 18